gsk.com

GSK FMC Tower at Cira
Centre South 2929
Walnut Street, Suite 1700
Philadelphia, PA 19104 T
+1 888 825 5249

May 2026

Important Carton Color Information

SUBJECT: SHINGRIX (Zoster Vaccine Recombinant, Adjuvanted) Prefilled Syringe Carton Color Change to Decrease Risk of Product Administration Error

Dear Health Care Provider,

The purpose of this letter is to inform you of a plan to revise the SHINGRIX prefilled syringe (PFS) carton label color following feedback from health care providers regarding the similarity between the colors of the SHINGRIX PFS carton which launched in the US on February 2, 2026, and the HAVRIX 720 EL.U./0.5 mL carton. The change involves updating the bar graphic color on the SHINGRIX PFS carton label from red to orange to reduce the risk of vaccine administration errors.

Action Taken by GlaxoSmithKline Biologicals (GSK)

To reduce the risk of incorrect vaccine administration, GSK is updating the SHINGRIX PFS carton color with the FDA:

- The SHINGRIX PFS carton color will transition from the current red color to the original SHINGRIX orange color currently used for the vial-vial presentation.
- The HAVRIX (720 EL.U./0.5 mL Hepatitis A Vaccine) carton color will remain unchanged.

During the transition period, health care providers may continue to receive SHINGRIX PFS with the current red carton color.

There is no impact to product quality, formulation, dosing, administration, storage conditions, or safety profile associated with this carton color change.

Action Required by Health Care Providers

As the existing SHINGRIX PFS and HAVRIX (720 EL.U./0.5 mL Hepatitis A Vaccine) carton colors remain approved and in market, please continue to follow standard medication safety practices, including verification of the product name, dose and other distinguishing product features.

Reporting Adverse Events

Health care providers and patients are encouraged to report adverse events in patients taking SHINGRIX or HAVRIX to:

- GSK via Patient Safety Reporting - Let's get started. (gsk.public.reportum.com) or 1-888-825-5249
- FDA at 1-800-822-7967 or www.vaers.hhs.gov for vaccines

Contact(s) for further information or questions

Contact GSK Medical Information at 1-877-356-8368 if you have any questions about the information contained in this letter or the safe and effective use of SHINGRIX or HAVRIX.

This letter is not intended as a complete description of the benefits and risks related to the use of SHINGRIX or HAVRIX. Refer to the full prescribing information (SHINGRIX Prescribing Info and HAVRIX Prescribing Info).

Sincerely,



Temi Folaranmi, MBChB, MPH, MPP
Vice President & Therapeutic Area Head, Vaccines
US Medical Affairs

Enclosure(s): SHINGRIX and HAVRIX Full Prescribing Information